Wockhardt Hospitals launches My Patient, My Idea initiative for nurses

IMT News Desk
IMT News Desk
· 2 min read

Nurses will be able to share innovative ideas that enhance patient care, improve experiences, and reduce healthcare costs

Wockhardt Hospitals launched ‘My Patient, My Idea’—a first-of-its-kind initiative aimed at empowering nurses to share innovative ideas that enhance patient care, improve experiences, and reduce healthcare costs.

Recognising nurses as frontline problem solvers, the initiative echoes the 2025 International Nurses Day theme, “Caring for Nurses, Strengthening Economies.” It provides a platform to acknowledge and reward the creativity, insight, and dedication of nursing professionals,
reinforcing their pivotal role in driving meaningful change within healthcare systems.

More than 950 nurses participated in the week-long festivities, which included meaningful ceremonies and vibrant activities designed to honor and uplift the nursing community. The celebration began with nurses uniting to sing the Wockhardt Anthem and recite the Nursing Pledge, reinforcing their shared mission of patient care. A special tribute was paid to nursing leaders, recognising their tireless service and leadership.

The events also featured creative competitions such as poster drawing, singing, and talent showcases, offering nurses a platform to express themselves beyond their professional roles.

Zahabiya Khorakiwala, MD, Wockhardt Hospitals, emphasised “Investing in the professional development and well-being of nurses is paramount to ensuring quality patient care. At Wockhardt, we provide ongoing training, mentorship, and educational support to empower nurses in their careers. Equally, we prioritise the wellness of our nurses with initiatives like mental health support, wellness days, and programs that promote work-life balance.”

Dr Parag Rindani, CEO, Wockhardt Hospitals, said, “Our nurses are the backbone of our healthcare delivery. Their resilience and compassion—especially in challenging times—are truly commendable. Wockhardt is proud to cultivate an environment that supports their growth and acknowledges their invaluable contributions.”

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk